Targets › EEF2
2 programs from 2 companies in 12 trials: 8 Phase 1, 4 Phase 2; Oncology; next expected readout Feb 2028.
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. (UniProt, P13639)
Open in Phaseline: the race on EEF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stemline Therapeutics | Tagraxofusp Interleukin-3 receptor subunit alpha binding agent; Elongation factor 2 inhibitor | IL3RA, EEF2 | Phase 2 | Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Myelofibrosis … | Feb 2028 |
| Alexander B Olawaiye, MD | Denileukin Diftitox (E7777) Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent | EEF2, IL2RA, IL2RG, IL2RB | Phase 1 | Epithelial Ovarian Cancer | May 2030 |
Acute Myeloid Leukemia (4) Epithelial Ovarian Cancer (1) Blastic Plasmacytoid Dendritic Cell Neoplasm (1) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1) Myelofibrosis (1) Chronic Myelomonocytic Leukemia (1) Refractory Acute Myeloid Leukemia (1) Hematologic Malignancy (1) Acute Myeloid Leukaemia (AML) (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.